System comparison
Emcyte PurePRP vs Selphyl
These are not two versions of the same product. Emcyte PurePRP SP prepares liquid platelet-rich plasma. Selphyl prepares PRFM, a platelet-rich fibrin matrix, by adding calcium chloride to convert the plasma into a fibrin scaffold. Before you compare specifications, decide which of those two things your protocol actually calls for.
Disclosure: PRP Direct is an Emcyte distributor. We have a commercial interest in one of the systems on this page. Every Selphyl figure below is quoted from Selphyl's own published material with a link and a date, including their growth-factor claim, which we attribute to them rather than restate or dispute. We do not make efficacy claims for our own products either.
The category difference comes first
Selphyl describes its output as Platelet-Rich Fibrin Matrix and positions it as the next generation of PRP. Mechanically, the system draws blood into a proprietary tube with a separator gel, spins once for about six minutes, transfers the plasma through a closed system into a second tube containing calcium chloride, and the calcium triggers fibrin polymerization that converts the PRP into a matrix.
That last step is the whole distinction. A liquid you inject and a polymerized matrix behave differently in the syringe, in the tissue, and in how you plan a case. Our PRP vs PRF guide covers what changes when fibrin forms.
So the honest first question is not "which is more concentrated." It is whether you want a measurable liquid dose or a fibrin scaffold. If it is the scaffold, we are not your supplier, and we would rather tell you that here than after you have spent an hour on a call.
Side by side
Selphyl figures are as published by Selphyl. Emcyte figures are manufacturer-reported. Rows are matched only where the two publish comparable information.
| Specification | Emcyte PurePRP SP | Selphyl |
|---|---|---|
| What it produces | Liquid platelet-rich plasma | Platelet-Rich Fibrin Matrix (PRFM) |
| Spins | 2 | 1, approximately 6 minutes |
| Conversion step | None; output stays liquid | Plasma transferred into a calcium chloride tube; fibrin polymerization |
| Cell separation method | Density separation across two spins | Separator gel; red and white cells retained below the gel |
| Platelet concentration published | ≥ 6x baseline | Not published as a concentration multiple |
| Leukocyte profile | Selectable, neutrophil-rich or neutrophil-poor | White cells described as retained below the separator gel |
| Output volume | 7 mL from the 60 mL kit | Not published; small blood draw described |
| Kit sizes | 30 / 60 / 120 mL | Tube-based kit; sizes not published on the product page |
| Other preparations on the same platform | Bone marrow concentrate, adipose, A2M ultrafiltration | Not published |
| Growth-factor release | No release-duration claim made | Selphyl states growth factors are released up to 7 days versus hours with traditional PRP |
Selphyl specifications and claims from selphyl.com (retrieved 2026-07-25), including the kit component list and the process description. The growth-factor release figure is Selphyl's own published claim, reproduced here as their statement. We have not independently evaluated it, and we make no competing release-duration claim for any product we sell. Emcyte specifications are manufacturer-reported. Rows marked not published are left that way because the manufacturer does not publish that figure on its public product page.
On the seven-day claim
Selphyl's central marketing argument is sustained growth-factor release from the fibrin matrix. We are not going to tell you it is wrong, because we have not evaluated it and it is not our claim to adjudicate. The mechanism it describes, a fibrin scaffold binding platelets and releasing over time, is a real and widely discussed rationale in the literature.
What we will say is what applies to every claim in this category, including ours: a mechanism is not an outcome, release kinetics measured in a tube are not a clinical result, and no PRP or PRFM preparation is FDA-approved to treat any condition. Ask any supplier, us included, to show you where a number came from and who paid for the study.
Where each one fits
- Selphyl fits aesthetic practices that specifically want a fibrin matrix rather than a liquid, and want a short single-spin workflow with a small draw.
- PurePRP SP fits practices injecting a measurable liquid dose, wanting a selectable leukocyte profile, or running orthopedic, bone marrow, and adipose cases on one centrifuge.
- If you are unsure which category you need, read the PRP vs PRF guide first. That decision determines the supplier, not the other way around.
Common questions
Is Selphyl the same as PRP?
Not quite. Selphyl produces PRFM, a platelet-rich fibrin matrix, by transferring plasma into a calcium chloride tube so fibrin polymerizes. Emcyte PurePRP produces liquid PRP with no conversion step. Selphyl positions PRFM as the next generation of PRP, but the physical output differs.
Does PRFM really release growth factors for seven days?
That is Selphyl's published claim and we reproduce it as theirs. We have not independently evaluated it and make no competing release-duration claim. Note generally that release kinetics measured in a tube are a mechanism, not a clinical outcome, whoever is making the claim.
Which has higher platelet concentration?
Emcyte publishes at least 6x baseline for PurePRP SP. Selphyl does not publish a concentration multiple on its public product page, so there is no like-for-like comparison to make. We are not going to estimate a number on another manufacturer's behalf.
Does PRP Direct sell Selphyl?
No. We distribute the Emcyte point-of-care line: PRP, bone marrow concentrate, adipose, and the A2M ultrafiltration component. If your protocol specifically calls for a fibrin matrix, we are not the right supplier and will say so.
Need a liquid PRP dose you can measure?
Tell us the cases you run. We'll send itemized pricing on the kits that match, within one business day. No login wall.
Request a quotePRP Direct is an Emcyte distributor. Competitor specifications and claims are quoted from the manufacturers' own published materials and are their statements, not ours. Devices referenced are cleared blood-processing devices; clearance covers how a device processes blood and is not a clearance of the prepared PRP or PRFM to treat any condition, and no PRP therapy is FDA-approved for a specific indication. Manufacturer specifications are not claims of clinical efficacy. This page is general education and is not medical advice. Product names and trademarks belong to their respective owners.